The 2026 dental M&A Thesis

Over the past two years, more than 40 DSOs were brought to market in the United States. But fewer than 10 closed. That's a 75% failure rate on platform exits, and the reason is not the financials, it's what the financials never showed.

For the last decade the dental DSO playbook ran on a single bet, that you could buy practices at four to six times EBITDA, roll them into a platform, and exit the platform at 9-14x. The math worked because multiple expansion was already happening, not something you had to necessarily earn. Operational execution at each acquired practice was treated as an integration problem that would sort itself out over time, and financial diligence was treated as sufficient because financial performance was the only thing the next buyer was going to price on.

That entire thesis is breaking right now, and most of the people inside it are still operating like the rules haven't changed.

The market evidence is no longer ambiguous

Lincoln International reported that over the past two years, more than 40 DSOs were brought to market in the United States and fewer than 10 transactions successfully closed. That is roughly a 75% platform exit failure rate, and a recurring theme in the post-mortems is operational reality at the practice level not matching what the platform told its eventual buyer, with the buyer's diligence team finding it, and the deal dying or getting repriced down to a number the seller would not accept.

Becker's Dental Review reported in January 2026 that very few DSOs are now offering more than 65-70% cash at close, with the rest sitting in holdback tied to operational performance post-close. In DSO transactions over the last few years, the percentage of cash at close has been compressing while the percentage held back against post-close performance has been growing. The cash that used to leave the table on closing day is now contingent on whether the practice actually performs the way it was sold to perform, and smaller DSOs are starting to have visible trouble releasing those holdback dollars to sellers a year or two later, which has begun circulating in the broker and seller community in a way that affects how the next deal gets structured.

Industry analysis through 2024 and 2025 consistently shows PE firms holding dental assets for an average of 6 years and longer, well beyond the 3-to-5 year hold model the original thesis was built around. So it's clearly not a matter of market timing, it's becoming a value creation execution problem, and the hold period is where it becomes visible because the operational reality of each tuck-in compounds at the platform level over time. The exit math no longer survives operational surprise.

The pressure stack underneath all of this is structural

Interest rates killed the cheap debt that powered LBO roll-ups. Lenders pulled leverage from around six and a half times EBITDA down closer to five. Entry multiples on tuck-ins crept up from the four-to-five times range into five-to-seven, which compressed the arbitrage from both ends. Hygienist labor shortages have persisted for three consecutive years and now constrain capacity at most multi-location groups. Insurance reimbursement has not kept pace with cost increases. Patients have started deferring elective treatment as economic pressure on households tightens. And the supply of clean acquisition targets has thinned, which has made each remaining good practice harder and more expensive to find.

A roll-up that worked at zero interest rates with abundant labor and easy multiple expansion does not work at 5% debt cost with hygiene staffing shortages and a six-to-eight times exit multiple ceiling. The arbitrage closed. What replaces it is not “no DSOs”, it's strategically operated DSOs. Platforms that actually know which practices to buy, why they are buying them, how to integrate them, and how to extract value from the operations rather than from financial engineering. That tier wins now. Everyone else either quietly recapitalizes, writes down LP capital, or sells at a haircut to whichever strategic acquirer is willing to take on the integration problem.

Underneath all of this is a deeper shift in what the return actually comes from. Because in the old world, the return came from the multiple. You bought at 5x, exited at 12x, and the spread was the return. Operational execution at each tuck-in mattered but did not have to be perfect because the exit multiple absorbed the variance. In the new world, with multiple compression and the exit market broken, the spread is no longer there to absorb anything. The return now has to come from running the specific practice better than the seller did, which means the buyer needs to know exactly where the recoverable upside lives inside that practice before they close the transaction, not after. In a market where multiple expansion no longer delivers the return, the alpha has to come from operations, from running the specific practice better than the seller did. And you cannot capture operational alpha you never documented.

This is the part of the thesis most buyers have not yet absorbed. The price they pay is still set by EBITDA times a multiple, that mechanic hasn't changed, but what has changed is the cost of being wrong about what is underneath that EBITDA. A deal that would have been a lesson learned in 2018 is a fund-economics-damaging miss in 2026. And a deal where the buyer captures upside the seller could not document is the difference between hitting fund targets and missing them.

To put a shape on it: on a typical six-location group, the recoverable operational layer routinely runs into the high six figures of annual production sitting uncaptured in the practice management system. At a 7x multiple, that is over a million dollars of enterprise value that nobody priced, on one tuck-in. Across a platform doing dozens of acquisitions a year, the compounding gap is not a rounding error. It is the difference between a fund that returns and a fund that struggles to raise its next vehicle.

The diligence stack every buyer runs today was built for the old thesis

Financial QoE answers what the practice earned. Organizational diligence addresses people risk. Commercial diligence looks at market position. But none of these answer the topic that matters now, which is what recoverable upside is sitting in the patient base that the trailing financials do not reflect, because none of these were designed to. That answer lives in the PMS data and the patient-level operations that produced those trailing earnings in the first place, and that layer is structurally outside the scope of every existing diligence discipline.

It goes without saying this is not a competence issue. Financial QoE firms know audit and accounting at an institutional level, and they are excellent at what they do. Dental consulting firms know operations and they help practice owners run better practices over months and years of engagement. Brokers facilitate transactions and represent their clients well. Internal operators run the business and know it intimately. Each of those roles is doing exactly what it is set up to do. The gap is what no role is set up to do, which is produce buyer-grade, forensic documentation of the patient-level operational layer in a format that belongs in a deal room and gets used as a transaction input.

Some forms of this work do exist at the edges of the industry, but each has a structural reason it cannot fill the gap.

• Major consulting firms have named full potential diligence as a concept and articulated why it matters, but they are built around six-figure-plus engagements on billion-dollar platform deals and do not run on a two-to-three week post-LOI timeline at lower-middle-market multiples.
• Some of the largest DSO platforms have built internal analytics capability that touches parts of this, but internal dashboards surface the score rather than the forensic diagnosis. The analysis is built post-close rather than delivered as pre-close diligence, and an acquirer's own internal read of a target it is buying carries less weight in the deal room than an independent document, the same reason buyers commission third-party financial QoE rather than relying on their own model.
• Practice management consultants understand the operational layer deeply but produce coaching engagements over months and years, not transaction-grade documentation formatted for a sophisticated buyer's investment committee.
• Some financial QoE firms have begun adding macro-level operational sections to their reports, which is genuinely useful but does not extend to patient-level PMS forensics.

The category of work that does not exist anywhere productized is patient-level operational forensics formatted as a transaction document, deliverable in the post-LOI diligence window, at lower-middle-market and mid-market dental deal economics. That is the specific gap.

The work of documenting that layer therefore does not get done. Buyers underwrite without it, close the acquisition, and discover the true operational picture themselves many months later when their integration team properly opens the PMS and starts pulling reports. Lapsed recall sitting recoverable, unscheduled treatment already accepted at full case value, provider production variance where standardizing the bottom performers to the median moves the EBITDA line, no-show patterns concentrated by location and by chair where capture rate improvements drop straight to margin. All of it has been sitting in the practice management software the entire time, waiting to be captured. But by the time the buyer's team finds it, the integration is already underway, the easy compounding window of months one through six has passed, and what should have been captured upside flowing through the hold period from day one has become a discovery exercise the operating team has to run on top of the business.

The seller leaves the upside on the table, the buyer captures it 12 to 18 months later than they could have, the broker's commission gets calculated against a smaller deal than the group warranted, the lender underwrites against earnings that do not necessarily reflect what the asset is actually capable of producing in the future, and everyone moves on to the next transaction with the same blind spot embedded in the playbook. The cycle repeats on the next deal.

What changes the cycle is a forensic read of the operational layer during diligence, in the window between LOI signature and close, running concurrent with the financial QoE

Not operational diligence in the traditional sense, which evaluates whether the business is well-run at the macro level. The piece of diligence that has been missing is patient-level forensics. It answers:

• What recoverable revenue is sitting in the PMS that never showed up in the trailing financials.
• Which scheduling and treatment-acceptance mechanics are producing the case volume, and which ones are leaving capture rate on the table.
• Where conversion is already happening and where the easy upside lives.
• Which provider variance, when closed, moves the EBITDA line by how much.
• Which patient cohorts have already lapsed and are recoverable, weighted by realistic reactivation probability.
• The exact dollar value of recoverable revenue sitting uncaptured in the practice management system, categorized by leakage type, with the operational root cause behind each category named so the integration team can execute against it from day one.

That picture exists for every practice, it always has. It has just never been extracted, organized, and packaged in a format that holds weight inside a deal room alongside the financial QoE. The data is in the PMS. The methodology to extract it requires forensic technique, deal-room formatting, and benchmark context that no current diligence discipline is structured to produce. Buyers cannot do this work pre-LOI because the seller has not yet granted PMS access. Buyers do not do it post-close because by then the integration is already running and the early-capture window has passed. The only window where the work belongs is post-LOI and pre-close, sitting alongside the financial QoE in the data room.

We named this layer of diligence the Operational Quality of Earnings, because the existing diligence stack did not have a name for it and it deserved one

DRAI was built specifically to produce it.

The deliverable is a transaction document, not a consulting report. It's structured the way a sophisticated buyer's investment committee expects a diligence finding to be structured, with the recoverable revenue quantified by category, the operational mechanic behind each category named and explained, and the recovery pathway described in terms the integration team can execute against from day one of ownership. It runs concurrent with the financial QoE, inside the same diligence window, on the same data room access the buyer already has under the LOI, with no incremental burden on the seller and no timeline impact on the deal. It is reviewed by the buyer's deal team alongside the financial QoE, and the investment committee approves the deal with full visibility into what the practice is actually capable of producing in the future rather than only what the trailing financials suggest.

The price the buyer pays does not necessarily change, what changes is the quality of the bet that price represents. A buyer paying 6x EBITDA on a practice where the recoverable operational upside is documented pre-close is making a different quality of bet than a buyer paying 6x on the same practice where that upside is unknown. Same dollars invested, but one buyer knows exactly what they're buying and the other is essentially making an expensive, risky assumption. The first buyer's integration team captures the upside in months one through six and the EBITDA improvement flows through the hold period from day one. The second buyer's team finds it once the practice is in their reporting stack, typically months after close, and starts capturing it later still, losing the early-compounding window that the new hold-period math cannot afford to lose.

That's why the buyers and platforms who make patient-level operational diligence part of how they underwrite, the ones who bring this analysis into the deal room rather than discovering the gaps after close, will own the next decade of dental PE.

The dental PE category is rewriting its rules right now. Every buyer already knows, in general terms, that operational upside exists inside the practices they acquire. That's not the gap. The gap is that nobody has quantified it at the patient level, in dollars, in a document that sits in the deal room and tells the integration team exactly where the recoverable EBITDA lives and how to capture it from day one.

General awareness is not alpha. Specificity is.

The buyers who bring that specificity into the deal room, rather than discovering it in month twelve, are the ones who come out the other side of this market owning what is left.